Inovio Pharmaceuticals Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer.
This open-label study, called HPV-004, will evaluate INO-3112 in 20 female subjects, with inoperable invasive cervical cancer.
This cervical cancer study is being conducted at the University of Chicago Medical Centre.